[HTML][HTML] Efficacy of canakinumab in patients with still's disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for …
A Vitale, V Caggiano, PP Sfikakis, L Dagna… - Frontiers in …, 2023 - frontiersin.org
Introduction The effectiveness of canakinumab may change according to the different times it
is used after Still's disease onset. This study aimed to investigate whether canakinumab …
is used after Still's disease onset. This study aimed to investigate whether canakinumab …
Efficacy of canakinumab in patients with Still's disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still's …
A Vitale, V Caggiano, PP Sfikakis, L Dagna… - FRONTIERS IN …, 2023 - research.unipd.it
Introduction: The effectiveness of canakinumab may change according to the different times
it is used after Still's disease onset. This study aimed to investigate whether canakinumab …
it is used after Still's disease onset. This study aimed to investigate whether canakinumab …
Efficacy of canakinumab in patients with Still's disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still's …
A Vitale, V Caggiano, PP Sfikakis… - Frontiers in …, 2023 - pubmed.ncbi.nlm.nih.gov
Introduction The effectiveness of canakinumab may change according to the different times it
is used after Still's disease onset. This study aimed to investigate whether canakinumab …
is used after Still's disease onset. This study aimed to investigate whether canakinumab …
Efficacy of canakinumab in patients with Still's disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still's …
A Vitale, V Caggiano, PP Sfikakis, L Dagna… - FRONTIERS IN …, 2023 - research.unipg.it
Introduction: The effectiveness of canakinumab may change according to the different times
it is used after Still's disease onset. This study aimed to investigate whether canakinumab …
it is used after Still's disease onset. This study aimed to investigate whether canakinumab …
[PDF][PDF] Maria Maslinska, National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
E Del Giudice, P Wiland, L Cantarini, A Vitale… - 2023 - iris.unipa.it
The treatment of Still's disease has advanced remarkably in the last few years, with
interleukin 1 (IL-1) inhibition representing an effective and safe treatment option in patients …
interleukin 1 (IL-1) inhibition representing an effective and safe treatment option in patients …
[PDF][PDF] Maria Maslinska, National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
E Del Giudice, P Wiland, L Cantarini, A Vitale… - 2023 - avesis.marmara.edu.tr
The treatment of Still's disease has advanced remarkably in the last few years, with
interleukin 1 (IL-1) inhibition representing an effective and safe treatment option in patients …
interleukin 1 (IL-1) inhibition representing an effective and safe treatment option in patients …
[PDF][PDF] Maria Maslinska, National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
E Del Giudice, P Wiland, L Cantarini, A Vitale… - 2023 - core.ac.uk
The treatment of Still's disease has advanced remarkably in the last few years, with
interleukin 1 (IL-1) inhibition representing an effective and safe treatment option in patients …
interleukin 1 (IL-1) inhibition representing an effective and safe treatment option in patients …
[HTML][HTML] Efficacy of canakinumab in patients with Still's disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for …
A Vitale, V Caggiano, PP Sfikakis, L Dagna… - Frontiers in Medicine …, 2023 - jglobal.jst.go.jp
Efficacy of canakinumab in patients with Still’s disease across different lines of biologic
therapy: real-life data from the International AIDA Network Registry for Still’s Disease …
therapy: real-life data from the International AIDA Network Registry for Still’s Disease …
Efficacy of canakinumab in patients with Still's disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still's …
A VITALE, V CAGGIANO, PP SFIKAKIS… - Frontiers in …, 2023 - observatorio.fm.usp.br
Introduction: The effectiveness of canakinumab may change according to the different times
it is used after Still's disease onset. This study aimed to investigate whether canakinumab …
it is used after Still's disease onset. This study aimed to investigate whether canakinumab …
Efficacy of canakinumab in patients with Still's disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still's …
A Vitale, V Caggiano, PP Sfikakis, L Dagna… - Frontiers in …, 2023 - europepmc.org
Methods Patients included in this study were retrospectively enrolled from the
AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to Still's disease …
AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to Still's disease …